miRecule is a biotechnology company that specializes in developing RNA therapies aimed at treating cancer and muscular dystrophy. Central to their approach is the proprietary DREAmiR™ discovery platform, which leverages genomic and clinical outcome data from thousands of patients to identify genetic abnormalities responsible for diseases. This platform enables the creation of tailored RNA therapeutics that directly target and rectify these genetic issues. miRecule's innovative pipeline includes lead programs focused on Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy (FSHD), showcasing their commitment to personalized medicine.

In addition to the DREAmiR™ platform, miRecule employs advanced RNA chemistry and targeted delivery mechanisms to enhance the efficacy and safety of their therapeutics. Their patented RNA sequences are chemically modified for improved stability and potency, while the use of antibody-RNA conjugates (ARCs) allows for precise delivery of these therapeutics to affected tissues. Collaborations with industry leaders, such as Sanofi, further bolster miRecule's capabilities, combining their RNA therapeutic innovations with Sanofi's NANOBODY® technology to develop groundbreaking treatments for rare genetic disorders like FSHD. This strategic partnership underscores miRecule's dedication to advancing next-generation RNA therapies that can significantly improve patient outcomes.

United States

We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD).

Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient.

Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

miRecule

Company Details